SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to reports of considering an all-cash bid for Warner Bros. Discovery, which the community is largely viewing as a bullish signal for avoiding dilution and indicating strong upcoming earnings. This comes amid an escalating takeover battle with Paramount, while many anticipate a pre-earnings rally or short squeeze ahead of its highly awaited report.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is a hot topic as investors analyze unaudited Q4 revenue and 2026 guidance for its multiple sclerosis treatment, Briumvi, ahead of an anticipated presentation at a major healthcare conference. The community is buzzing about Briumvi's strong market adoption and competitive advantages, further bolstered by recent issues impacting rival treatments. Despite operational strength, widespread discussion centers on the stock's valuation and the ongoing debate between its fundamental growth and market sentiment.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is experiencing significant volatility, primarily driven by continued discussions around executive share sales and recent concerns regarding new AI agent solutions entering the market. While some investors see market manipulation in the stock's rapid movements, many within the community view current levels as a compelling buying opportunity, emphasizing the company's robust balance sheet and its strategic position in the burgeoning agentic AI sector.

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is trending as a high-leverage play on the Injective (INJ) ecosystem, which is gaining significant attention for its robust developer activity, strong revenue performance, and institutional interest, including staked ETF filings. The community is actively discussing NONJA's unique resilience, high burned liquidity, and dedicated base, positioning it for substantial upside as Injective's undervalued chain continues to grow.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending amid a barrage of analyst downgrades, as concerns over a challenging AI technology transition and intensifying competition from rival creative software and AI tools fuel a heated debate among investors. While many view the stock as overvalued and vulnerable to disruption, a significant segment of the community sees the recent dip as a compelling buying opportunity, emphasizing Adobe's strong fundamentals and strategic AI integrations for long-term growth.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging amid positive financial outlook revisions and ongoing regulatory progress for its next-generation COVID and flu vaccines, complemented by funding for a pandemic flu trial. Community discussion centers on the company's perceived undervaluation and the long-term potential of its diverse mRNA pipeline, particularly in oncology, with many anticipating a substantial short squeeze. This renewed interest highlights a broader re-evaluation of Moderna's platform capabilities within the evolving biotech landscape.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery (WBD) is trending as it navigates an escalating takeover battle, with its board reportedly favoring Netflix's acquisition proposal over Paramount Skydance's (PSKY) all-cash offer, despite a personal financing guarantee. The community is buzzing with debate, weighing PSKY's perceived superior value and the potential for a significantly higher bid from either contender to secure market dominance in the evolving media landscape. Shareholders are closely watching for definitive developments in this strategic consolidation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics (CADL) is trending amid intense community speculation regarding an imminent major partnership or acquisition, with Novartis frequently mentioned as a potential suitor. This excitement is amplified by the upcoming J.P. Morgan Healthcare Conference, a hub for anticipated biopharma M&A, and recent FDA flexibility on CMC requirements, which could accelerate the BLA submission for its lead prostate cancer drug, CAN-2409. The community is actively debating the company's current low valuation against its promising clinical data, eagerly anticipating a transformative deal or further clarity on its expedited regulatory path.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending due to its strong Q3 earnings report, which exceeded EPS expectations and included an optimistic FY26 revenue forecast, significantly driven by the accelerating adoption of its AI-powered Agentforce platform. This has ignited bullish sentiment among investors who see the stock as deeply undervalued and poised for a rebound. However, community discussion continues to reflect broader market skepticism about AI's impact on traditional software licensing models and the stock's past volatility.

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. The company was founded on October 26, 2023 and is headquartered in Dubai, United Arab Emirates.

Ambitions Enterprise Management Co LLC - Ordinary Shares - Class A

Ambitions Enterprise Management Co LLC

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BillionToOne Showcases Single-Molecule NGS at JPMorgan, Lifts 2025 26 Revenue Outlook

Billiontoone (NASDAQ:BLLN) used its presentation at the JPMorgan Healthcare Conference to highlight what management described as a single molecule next-generation sequencing platform that it believes...

Billiontoone (NASDAQ:BLLN) Trading Up 9.4% - Should You Buy?

Billiontoone (NASDAQ:BLLN) Trading 9.4% Higher - Here's What Happened...

BillionToOne Backs Annual Outlook; Initiates 2026 Revenue Guidance Above View

(RTTNews) - BillionToOne, Inc.(BLLN), a molecular diagnostics company, on Monday reaffirmed its outlook for fiscal 2025 and initiated guidance for 2026...

Billiontoone (NASDAQ:BLLN) Now Covered by Guggenheim

Guggenheim initiated coverage on Billiontoone in a report on Tuesday. They issued a "buy" rating and a $120.00 price target on the stock...

BillionToOne Announces Selection of Northstar Select as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East

BillionToOne Announces Selection of Northstar Select as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East BillionToOne Announces Selection of...

Billiontoone (NASDAQ:BLLN) Reaches New 52-Week Low - Here's Why

Billiontoone (NASDAQ:BLLN) Reaches New 12-Month Low - Here's Why...

Billiontoone (NASDAQ:BLLN) Trading Up 3.2% - Time to Buy?

Billiontoone (NASDAQ:BLLN) Trading 3.2% Higher - What's Next...

Billiontoone, Inc. (NASDAQ:BLLN) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are covering the company, MarketBeat.com reports...

Billiontoone (NASDAQ:BLLN) Trading Down 5.8% - What's Next?

Billiontoone (NASDAQ:BLLN) Stock Price Down 5.8% - What's Next...

Greenberg Traurig Represents BillionToOne Inc. in $314M Initial Public Offering

Greenberg Traurig Represents BillionToOne Inc. in $314M Initial Public Offering Greenberg Traurig Represents BillionToOne Inc. in $314M Initial Public Offering PR Newswire HOUSTON, Dec. 12, 2025...

BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. The company’s patented Quantitative Counting Templates (QCT) molecular counting platform is a multiplex technology capable of accurately counting DNA molecules at the single-molecule level. BillionToOne was founded by Oguzhan Atay, Sukrit Silas, and David Tsao in 2016 and is headquartered in Menlo Park, CA.

Billiontoone Inc. - Ordinary Shares - Class A

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$96.85
Prev Close	$99.15
Open	$99.85
Dividend Yield	N/A
50-Day Moving Average	$99.01
Beta	0.00
Avg. Volume	210,730.14
PE Ratio	-311.40

52-Week High	$138.70
52-Week Low	$60.00
Market Capitalization	$4.54B
EPS (Annual)	-$0.9296
Price to Book	-18.95
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

BLLN
Billiontoone Inc. - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BLLN News

BLLNBilliontoone Inc. - Ordinary Shares - Class A